Appointment of Nominated Adviser and Broker
Belfast and London, 2 September 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry is pleased to announce the appointment of Canaccord Genuity Limited as the Company's Nominated Adviser and Broker, with immediate effect.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
|
Alma Strategic Communications |
Tel: +44(0)20 3405 0205 |
|
Caroline Forde, Kinvara Verdon
|
diaceutics@almastrategic.com |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
